Roblin Xavier, Cavaille Alaric, Clavel Léa, Paul Stéphane
CHU de Saint-Étienne, hôpital Nord, service de gastro-entérologie, 42277 Saint-Priest-en-Jarez, France.
CHU de Saint-Étienne, hôpital Nord, service de chirurgie digestive, 42277 Saint-Priest-en-Jarez, France.
Presse Med. 2014 Jan;43(1):66-73. doi: 10.1016/j.lpm.2013.11.004. Epub 2013 Dec 27.
Fecal calprotectine is of interest for diagnosis of IBD at the beginning. CRP and fecal calprotectine are predictive of long-term response in patients treated by anti-TNF therapy. Trough levels of anti-TNF are associated to clinical remission and mucosal healing. Detectable antibodies to anti-TNF are associated with lower response to treatment. Interventional studies are waiting before optimization of treatment in function of biomarkers. Trough levels of anti-TNF help to modify our treatment (optimization or de-escalation).
